Abstract:Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions. Although this finding has been met with enthusiasm, ketamine’s widespread use is limited by its abuse potential and dissociative properties. Recent preclinical research has focused on unraveling the molecular mechanisms underlying the antidepressant actions of ketamine in an effort to develop novel pharmacotherapies, which will mimic ketamine’s antidepressant actions but lack its undesirable effects. Here we review hypotheses for the mechanism of action of ketamine as an antidepressant, including synaptic or GluN2B-selective extra-synaptic N-methyl-D-aspartate receptor (NMDAR) inhibition, inhibition of NMDARs localized on GABAergic interneurons, inhibition of NMDAR-dependent burst firing of lateral habenula neurons, and the role of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor activation. We also discuss links between ketamine’s antidepressant actions and downstream mechanisms regulating synaptic plasticity, including brain-derived neurotrophic factor (BDNF), eukaryotic elongation factor 2 (eEF2), mechanistic target of rapamycin (mTOR) and glycogen synthase kinase-3 (GSK-3). Mechanisms that do not involve direct inhibition of the NMDAR, including a role for ketamine’s (R)-ketamine enantiomer and hydroxynorketamine (HNK) metabolites, specifically (2R,6R)-HNK, are also discussed. Proposed mechanisms of ketamine’s action are not mutually exclusive and may act in a complementary manner to exert acute changes in synaptic plasticity, leading to sustained strengthening of excitatory synapses, which are necessary for antidepressant behavioral actions. Understanding the molecular mechanisms underpinning ketamine’s antidepressant actions will be invaluable for the identification of targets, which will drive the development of novel, effective, next-generation pharmacotherapies for the treatment of depression.

Brain region-specific action of ketamine as a rapid antidepressant

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

Ketamine blocks bursting in the lateral habenula to rapidly relieve depression

A role of GABAA receptor 1 subunit in the hippocampus for rapid-acting antidepressant-like effects of ketamine

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research

Lateral Habenular Burst Firing As a Target of the Rapid Antidepressant Effects of Ketamine.

A role of GABA A receptor α1 subunit in the hippocampus for rapid-acting antidepressant-like effects of ketamine

NMDA antagonist treatment of depression

Sustained Antidepressant Effect of Ketamine Through NMDAR Trapping in the LHb

Ketamine May Exert Rapid Antidepressant Effects Through Modulation of Neuroplasticity, Autophagy, and Ferroptosis in the Habenular Nucleus.

The N-methyl-d-aspartate receptor hypothesis of ketamine's antidepressant action: evidence and controversies

Uncovering the Underlying Mechanisms of Ketamine As a Novel Antidepressant

Rapid and sustained restoration of astrocytic functions by ketamine in depression model mice

Mechanisms of ketamine action as an antidepressant

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

Serotonergic transmission plays differentiated roles in the rapid and sustained antidepressant-like effects of ketamine

Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration

The Neurobiological Mechanism Underlying Ketamine’s Rapid-Acting Antidepressant Effect

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

Ketamine's rapid and sustained antidepressant effects are driven by distinct mechanisms